COMT inhibition with tolcapone does not affect carbidopa pharmacokinetics in parkinsonian patients in levodopa/carbidopa (Sinemet). [electronic resource]
Producer: 19991116Description: 449-52 p. digitalISSN:- 0306-5251
- Aged
- Antiparkinson Agents -- pharmacokinetics
- Benzophenones -- pharmacology
- Carbidopa -- pharmacokinetics
- Catechol O-Methyltransferase -- metabolism
- Catechol O-Methyltransferase Inhibitors
- Drug Combinations
- Drug Interactions
- Enzyme Inhibitors -- pharmacology
- Female
- Humans
- Levodopa -- therapeutic use
- Male
- Middle Aged
- Nitrophenols
- Parkinson Disease -- drug therapy
- Tolcapone
No physical items for this record
Publication Type: Clinical Trial; Journal Article
There are no comments on this title.
Log in to your account to post a comment.